Sol-Gel Technologies (SLGL) Total Non-Current Liabilities (2016 - 2025)
Sol-Gel Technologies (SLGL) reported Total Non-Current Liabilities of $935000.0 for Q4 2025, down 45.35% year-over-year from $1.7 million in Q4 2024, and down 61.3% on a QoQ basis from $2.4 million in Q3 2025.
Sol-Gel Technologies (SLGL) has 10 years of Total Non-Current Liabilities data on file, last reported at $935000.0 in Q4 2025.
- Quarterly Total Non-Current Liabilities fell 45.35% year-over-year to $935000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $935000.0 (down 45.35% YoY) and the FY2025 annual result came in at $935000.0, down 45.35% from the prior year.
- Total Non-Current Liabilities slipped to $935000.0 in Q4 2025 per SLGL's latest filing, from $2.4 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $2.5 million in Q2 2025 and bottomed at $935000.0 in Q4 2025.
- The 5-year median for Total Non-Current Liabilities is $1.9 million (2021), against an average of $1.8 million.
- The widest annual swing landed in 2023, when Total Non-Current Liabilities surged 95.3%; it then slumped 45.35% in 2025.
- Tracing SLGL's Total Non-Current Liabilities over 5 years: stood at $1.9 million in 2021, then slumped by 42.93% to $1.1 million in 2022, then surged by 95.3% to $2.1 million in 2023, then decreased by 19.33% to $1.7 million in 2024, then tumbled by 45.35% to $935000.0 in 2025.
- Per Business Quant, the three latest SLGL Total Non-Current Liabilities figures stand at $935000.0 (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | 935,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 935,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | 2.04 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.23 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 1.22 Mn |
| Jun 30, 2022 | 1.41 Mn |
| Mar 31, 2022 | 1.72 Mn |
| Dec 31, 2021 | 1.90 Mn |
| Sep 30, 2021 | 1.86 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 2.09 Mn |
| Dec 31, 2020 | 2.35 Mn |
| Sep 30, 2020 | 2.09 Mn |
| Jun 30, 2020 | 2.20 Mn |
| Mar 31, 2020 | 2.26 Mn |
| Dec 31, 2019 | 2.33 Mn |
| Sep 30, 2019 | 1.17 Mn |
| Jun 30, 2019 | 1.28 Mn |
| Mar 31, 2019 | 1.39 Mn |
| Dec 31, 2018 | 878,000.00 |
| Sep 30, 2018 | 907,000.00 |
| Mar 31, 2018 | 932,000.00 |
| Dec 31, 2017 | 810,000.00 |
| Dec 31, 2016 | 694,000.00 |